The Role of Exosomes in the Female Reproductive System and Breast Cancers

Abstract

Exosomes are nanoscale extracellular vesicles released by nearly all cell types. Exosomes were originally considered as waste receptacles for discarding unwanted cellular products; however, these organelles are now considered to be important for cell communication by delivering biologically active molecules such as proteins, DNA, non-coding RNA and mRNA. Studies have revealed that exosomes are closely related to several diseases, especially cancers. Exosomes are indispensable for the emergence and progression of tumor. Here, we review the status of research on exosomes in the female reproductive system cancers and breast cancer, focusing on their biological roles in chemical resistance and immune responses, as well as their underlying applications in drug delivery and nanotherapy and as biological markers for tumor diagnosis.

Introduction

Cancers of the female reproductive system, including cervical cancer (CC), ovarian cancer (OC) and endometrial cancer (EC), as well as breast cancer (BC) are significant causes of death among women, and their incidence continues to increase. Despite advances in chemotherapy, radiation therapy and surgery in recent years, there is still a lack of methods for early diagnosis and effective treatment. A better comprehension of the potential molecular mechanisms of carcinogenesis and developments in particular biological markers are therefore needed.

The tumor environment is composed of tumor cells and non-stationary cells with diverse types of endocellular communication mechanisms.¹ In recent years, more and more research has been conducted on exosomes derived from diverse cancer and non-cancer cells.² Exosomes play a crucial role in establishing intercellular communication and maintaining tumor cell homeostasis. These vesicles shuttle miscellaneous biomolecules to target cells and are released from tumor cells. Therefore, analysis of tumor-derived exosomes may offer useful markers for precise monitoring of cancers.³ Tumor-derived exosomes also mediate immune responses and drug resistance in tumors, and can transfer endogenous and exogenous compounds making them good candidates for the delivery of nanotech drugs. Here, we review the progress in our understanding of the use of exosomes for the diagnosis and treatment of female reproductive system cancers and BC.

Biogenesis and Characterization

Exosomes are the most widely studied of the three major subunits (exosomes, microvesicles, and apoptotic vesicles (ApoEVs) of extracellular vesicles (EVs) liberated from mammiferous cells.^4,5 In addition to these three primary hypotypes, other EVs include membrane particles, exosome-like particles, EVs derived from neutrophils,⁶ EVs from the prostate,^7,8 migrasomes,⁹ large liposomes¹⁰ and others.¹¹ There are various names for exosomes in the literature: exosomes, oncosomes, dexosomes, exosome-like particles, and membrane blebs. Exosomes originate from the multivesicular body (MVB) and are cup-shaped when viewed under an electron microscope, with a diameter of 50–150 nm.¹² ApoEVs comprise nucleoprotein histones and DNA, with a diameter of 1000–5000 nm.¹³ Exosomes are produced by all normal and pathological cells and coexist in all body fluids, including plasma, urine, saliva, amniotic fluid, ascites, and cerebrospinal fluid.⁴ Each exosome carries the imprint of the contents of its parent cell, including nucleic acids, proteins, enzymes, lipids, cytokines, and other soluble factors, depending on the cell of origin, environmental conditions, stage of development, epigenetic variations, and biogenesis.^13,14 Messenger RNA (mRNA), microRNA (miRNA), ribosomal RNA (rRNA), transfer RNA (tRNA), and long non-coding RNA (lncRNA)¹⁵ have also been identified in exosomes, providing insights into the epigenetic modifications of cells and changes in their biological activity and function. The biogenesis of exosomes differs from that of other EVs.^16,17 Studies of the maturation of sheep reticular cells in the 1980s revealed that exosomes were generated by intracellular budding (Figure 1) through the plasmalemma to shape endocellular endosomes and achieve cell surface protein expression.¹⁶ More invasion of endocellular endosomes results in the production of MVB, which contain vesicles with diameters ranging from 40–150nm. Subsequently, the MVB fuses with lysosomes to degrade inclusions, or release their inclusions into the extracellular space accompanied by serosomes,¹⁷ a process known as exosome biogenesis.

Figure 1.

Biogenesis and content of exosomes.

Notes: Internal germination of the plasmalemma results in the construction of primitive endosomes that bind panniculus proteins. The entrapment of the endosome and encapsulation of the selected cargo (such as nucleic acids and proteins) then leads to the production of MVBs through ESCRT-dependent or ESCRT-independent mechanisms. These MVBs then fuse with the plasmalemma, releasing exosomes to the environment outside the cell. Exosomes transfer the cargos (proteins, mRNAs, miRNAs, lncRNAs, circRNAs, and DNAs) to recipient cells through mechanisms that include a) direct fusion, b) surface protein binding, and c) endocytosis.

The mechanisms of exosomal biogenesis are highly regulated via respective pathways,¹⁸ including endosomal sorting complexes required for transport ESCRT-dependent and ESCRT-independent pathways. In the mechanism of ESCRT panniculus rupture, exosome biogenesis requires four multiprotein subcomplexes (ESCRT-0, ESCRT-I, ESCRT-II and ESCRT-III). Inchoate ESCRT composites (ESCRT-0, ESCRT-I, and ESCRT-III) discern the ubiquitinated cargo through their ubiquitin-bonding subgroups to form steady protein composites in the protoplasm. ESCRT-III is then assembled instantly on the nucleosome and undergoes vesicle division.¹⁹ Recently, it has been shown that a number of assistant elements, such as ATPase, vacuolar protein sort-associated protein (VPS4) and ALG-2 interacting protein X (ALIX), are involved in the mechanism of ESCRT panniculus rupture.¹⁹ By comparison, the liberation of exosomes via the ESCRT-independent pathway is mediated by lipids, like spinolamide,²⁰ spinol-1-phosphate, and Rab family proteins, including Rab27a and Rab27b.²¹ Exosomes export many proteins that are promoters or inhibitors of tumors.²² For example, the widespread presence of heat shock proteins, p53, phosphatase, and tension protein homologues in exosomes is closely associated with tumor development.^23–26 MiRNAs in exosomes account for the majority of circulating miRNAs and have been studied as biomarkers of different cancers.²⁷ These discoveries suggest that exosomes are vital in the development of tumors.

The Functions of Exosome-Derived Cargos in Female Reproductive System Cancers and Breast Cancer and Their Underlying Roles as Biomarkers

Exosomes are pivotal adjusters of cell-cell communication and crucial adjective in the occurrence and development of tumor (Figure 2). Exosomes in cyclic body fluids serve on biomarkers in tumor diagnosis. Exosomes have been discerned in a variety of biosomes, which provides information that allows elucidation of their biogenesis and identification of their cells of origin as well as their biological functions.²⁸ Knowledge of exosomes in female reproductive system cancers and BC is still at a preliminary stage. Here, we discuss various components of exosomes in female reproductive system cancers and BC as well as other cells in the tumor microenvironment, including exosomal proteins (Table 1), miRNAs (Table 2), lncRNAs, circular RNAs (circRNAs), and DNAs (Table 3).

Figure 2.

Roles of tumor cells derived exosomes in female reproductive system cancer and breast cancers.

Notes: Exosomes are of great importance in the advancement of tumorigenesis, metastasis, angiogenesis, immune avoidance and drug resistance by the transfer of functional biomolecules. Exosomes from female reproductive system cancers and breast cancers can regulate immunity by inducing immune escape of γδT1 cells and immunosuppression of CD4+ T cells. Exosomes from female reproductive system cancers and breast cancers not only transport miRNAs from tumor cells to vascular endothelial cells to facilitate proliferation, invasion, migration and angiogenesis, but also act on tumor stromal cells to produce a beneficial microenvironment for tumor metastasis. Moreover, exosomes secreted by CAF promote EMT, cell propagation, invasion and migration. In addition, proteins, miRNAs, lncRNAs, circRNAs and DNAs in exosomes in circulating body fluids can be used as biomarkers for tumor diagnosis.

Table 1.

Overview of Exosomal Proteins and Functions in Female Reproductive System Cancer and Breast Cancers

Cancer	Protein	Recipient Cell	Pathway	Function	Reference
Breast CA	Heat shock protein 70 (HSP70)	Breast CA cells	N/A	Biomaker	[29]
Breast CA	Heat shock protein, enolase 1 alpha, S100, and biliverdin reductase B	Breast CA cells	N/A	↑migration and invasion	[30]
Breast CA	Platelet-reactive protein 1 (TSP1)	Breast CA cells	Destroying the intercellular integrity of endothelial cells	↑migration	[31]
Breast CA	Lactate dehydrogenase C4 (LDH-C4)	Breast CA cells	N/A	Biomaker	[32]
Breast CA	Membrane coupling protein A2 (AnxA2)	Breast CA cells	N/A	↑angiogenesis and metastasis	[33]
Breast CA	Matrix metalloproteinase2 (MMP2) and matrix metalloproteinase2 (MMP9)	Breast CA cells	N/A	↑proliferation, migration, invasion and resistance	[107]
Ovarian CA	Integrin protein α6, αv, and β1	Epithelial CA cells	N/A	Biomaker	[34]
Ovarian CA	CD24	Ovarian CA cells	N/A	Biomaker	[35]
Ovarian CA	Tubulin beta 3 chain (TUBB3), epithelial cell surface antigen (EpCAM), claudin 3 (CLDN3), proliferating cell nucleus antigen (PCNA)	Ovarian CA cells	N/A	Biomaker	[36]
Ovarian CA	v-type collagen 2 chain (COL5A2) and lipoprotein lipase (LPL)	Ovarian CA cells	N/A	Biomaker	[37]
Ovarian CA	Small heat shock protein(sHsp)	Ovarian CA cells	N/A	Biomaker	[100]
Ovarian CA	Plasma gelsolin (pGSN)	Ovarian CA cells	N/A	↑resistance	[113]
Ovarian CA	DNA methyltransferase 1 (DNMT1)	Ovarian CA cells	Stimulating endogenous expression	↑resistance	[116]
Cervical CA	Hh protein	Cervical CA cells	N/A	Biomarker	[38]

Table 2.

Overview of Exosomal miRNAs and Functions in Female Reproductive System Cancer and Breast Cancers

Cancer	miRNA	Recipient Cell	Pathway	Function	Reference
Breast CA	miR-1910-3p	Breast CA cells	NF-κB and wnt/β-catenin	↑Tumor cell growth	[39]
Breast CA	miR-181D-5p	Breast CA cells	CDX2 and HOXA5	↑EMT	[40]
Breast CA	miR-4516	Breast CA cells	FOSL1-dependent TNBC	↑proliferation and malignancy	[41]
Breast CA	miR-3613-3p	Breast CA cells	Targeting the expression of SOCS2	↓proliferation and metastasis	[42]
Breast CA	miR-27a-3p	γδT1 cells	Up-regulating PD-L1 through the MAGI2/PTEN/PI3K	↑immune escape	[86]
Breast CA	miR-221-3p	Breast CA cells	Targeting PIK3R1 through the PI3K/AKT	↑resistance	[109]
Breast CA	miR-155	Breast CA cells	N/A	↑resistance	[110]
Ovarian CA	miR-221-3p	Ovarian CA cells	Inhibiting CDKN1B	↑progression and ↓prognosis	[48]
Ovarian CA	miR-141-3p	Endothelial cells	Raising VEGFR-2 expression	↑migration and angiogenesis	[49]
Ovarian CA	miR-205	Endothelial cells	PTEN-AKT	↑angiogenesis and metastasis	[50]
Ovarian CA	miR21	Ovarian CA cells	Combinng with APAF1	↓apoptosis	[51]
Ovarian CA	miR-29a-3p and miR-21-5	CD4+ T cells	Suppressing STAT3 and regulating Treg/Th17 cells	↑progression and metastasis	[94]
Ovarian CA	miR-21-3p, miR-21-5p and miR-891-5p	Ovarian CA cells	Upregulating detoxification metabolic pathways and DNA repair mechanisms	↑resistance	[112]
Ovarian CA	miR-223	Hypoxic macrophages	PTEN-PI3K/AKT	↑resistance	[114]
Ovarian CA	miR-1246	Ovarian CA cells	Targeting Cav1	↑resistance	[117]
Ovarian CA	miR-98-5p	Ovarian CA cells	Inhibiting CDKN1A expression	↑resistance	[118]
Ovarian CA	miR-199a-3p	Ovarian CA cells	Inhibiting the expression of C-Met	↓proliferation and invasion	[125]
Cervical CA	miR-221-3p	Endothelial cells	Regulating MAPK10	↑proliferation, invasion, migration and angiogenesis	[53]
Cervical CA	miR-221-3p	Endothelial cells	Down-regulating THBS2	↑angiogenesis	[54]
Cervical CA	miR-155-5p	Cervical CA cells	Secreting pro-inflammatory cytokines (including IL-6 and IL-8)	↑malignancy	[55]
Endometrial CA	miR-133a	Endometrial CA cells	Down-regulating FOXL2	↑progression	[57]
Endometrial CA	miR-148b	Endometrial CA cells	Binding to its downstream target gene DNMT1	↓metastasis	[59]
Endometrial CA	miR-320a	Endometrial CA cells	Down-regulating HIF1 by miR-320a, leading to decreased expression of VEGFA	↓proliferation	[128]

Table 3.

Overview of Exosomal lncRNAs, circRNAs, DNAs and Functions in Female Reproductive System Cancer and Breast Cancers

Cancer	lncRNA/circRNA/DNA	Recipient Cell	Pathway	Function	Reference
Breast CA	lncRNA H19	Breast CA cells	N/A	Biomarker	[60]
Breast CA	lncRNA HOTAIR	Breast CA cells	N/A	Poor neoadjuvant chemotherapy and response to tamoxifen therapy	[65]
Breast CA	lncRNA SNHG16	Breast CA cells	SNHG16/miR-16-5p/SMAD5/CD73	Therapy	[90]
Breast CA	lnc RNA AFAP1-AS1	Breast CA cells	Binding to AU binding factor 1 (AUF1) and promoting ERBB2 translation	↑trastuzumab resistance	[108]
Breast CA	lncRNA-SNHG14	Breast CA cells	N/A	↑resistance	[111]
Ovarian CA	lncRNA FAL1	Ovarian CA cells	Inhibiting the PTEN/AKT	↓metastasis	[66]
Ovarian CA	lncRNA aHIF	Ovarian CA cells	N/A	Biomarker	[67]
Ovarian CA	lncRNA MALAT1	Human umbilical vein endothelial cells	Affecting angiogenesis(VEGF-A, VEGF-D, ENA-78, PlGF, IL-8, angiogenin, bFGF and leptin)	Inhibiting the activity of caspase-3 and affecting apoptosis-related proteins	[69]
Ovarian CA	lncRNA UCA1	Ovarian CA cells	inhibiting UCA1 to promote the expression of miR-143 and regulate the expression of FOSL2	↑resistance	[115]
Ovarian CA	circPUM1	Peritoneal mesothelial cells	Upregulating the expression of NF-kB and MMP2 by spongizing miR-615-5p and miR-6753-5p	↑proliferation, migration and invasion	[76]
Ovarian CA	wb-mtDNA	Ovarian CA cells	N/A	↑progression	[82]
Cervical CA	LncRNA-EXOC7	Cervical CA cells	N/A	Important biomarkers for diagnosis, evaluation of efficacy and detection of recurrence	[70]
Cervical CA	lncRNA HOTAIR, lncRNA MALAT1 and lncRNA MEG3	Cervical CA cells	N/A	Biomarker	[71]
Cervical CA	lncRNA TUG1	Cervical CA cells	N/A	↑proliferation and ↓apoptosis	[72]
Cervical CA	lncRNA TUG1	Cervical CA cells	Inhibiting the activity of caspase-3 and affecting apoptosis-related proteins	↑angiogenesis	[73]
Cervical CA	lncRNA HNF1A-AS1	DDP-resistant cells	Acting as the competitive endogenous RNA (ceRNA) of miR-34b, promoting the expression of TUFT1	↑resistance	[119]
Cervical CA	hsa-circRNA-0005795 and hsa-circRNA-0088088	Cervical CA cells	N/A	improve the diagnosis and therapy	[75]
Cervical CA	circEIF4G2	Cervical CA cells	N/A	biomarker	[77]
Cervical CA	ATF1 and RAS	Cervical CA cells	N/A	biomarker	[79]

Exosomal Proteins

Proteins are the dominating elements of exosomes, and the proteomic profile has attracted increasing attention, especially in the areas of cancer growth and metastasis. Chanteloup et al found that heat shock protein 70 (HSP70) was prominently elevated in adtevak exosomes from BC patients, and circulating HSP70 exosomes were increased in metastatic patients. These observations suggested that HSP70-exosome levels are negatively correlated with response to treatment, and monitoring changes in circulating HSP70-exosome levels may help to predict tumor response and clinical outcomes in BC.²⁹ Mohammed et al detected significantly upregulated exosomal proteins, including heat shock proteins, enolase-1-alpha, S100, and biliverdin reductase B in the lymph nodes of mice with metastatic BC, demonstrating that these exosomal proteins are involved in regulating tumor cell migration and invasion.³⁰ Cen et al verified that platelet-reactive protein 1 (TSP1) was extraordinarily expressed in exosomes derived from BC cells and demonstrated significantly increased migration of BC cells in animal models injected with overexpressed TSP1. The results suggested that cancer-derived exosome TSP1 promotes the transendothelial transplantation of BC cells by destroying the cell-cell wholeness of endothelial cells, thus implicating exosomal TSP1 as a biomarker of BC progression.³¹ Cui et al found that the mRNA expression level of lactate dehydrogenase C4 (LDH-C4) in serum and serum-derived exosomes of BC patients was relatively high. Furthermore, it was discovered that serum and exosomal levels of LDH-C4 were negatively correlated with drug therapy, positively correlated with BC recurrence, and negatively correlated with prognosis. This suggested that LDH-C4 derived from serum and exosomes may be an effective indicator for diagnosis of BC, evaluation of treatment efficacy and monitoring BC recurrence.³² Membrane coupling protein A2 (AnxA2) is associated with exosomes and promotes angiogenesis and metastasis. Chaudhary et al found that exo-AnxA2 was highly expressed in the sera of triple negative breast cancer (TNBC) patients and promoted angiogenesis. These findings suggested that exo-AnxA2 represents a potential prognostic factor for TNBC and indicated its value for the development of effective treatment options.³³ Integrins are vitally important in extracellular matrix attachment and signal conduction, and are involved in cell proliferation and migration. Hurwitz et al found the total levels of exosomal proteins, including integrin proteins α6, αv, and β1, is associated with tumor staging in a variety of epithelial cancers. Furthermore, integrin protein α6 largely reflects the expression of breast and ovarian progenitor cells, emphasizing the potential of exosomal integrin protein α6 as a circulating biomarker of BC and OC.³⁴ Soltesz et al showed that expression of the small molecule cell surface protein, CD24, was higher in exosomes derived from the tissues of serous OC patients compared with that in the control group. Furthermore, CD24 was found to be related to FIGO classification, which may be of significance for the diagnosis and monitoring the progression of serous OC.³⁵ Liang et al found that many proteins in OC tissues and secrete have expression, including tubulin beta 3 chain (TUBB3), epithelial cell surface antigen (EpCAM), claudin 3 (CLDN3) and proliferating cell nucleus antigen (PCNA). These proteins represent potential diagnostic markers and therapeutic targets in OC.³⁶ Cheng et al conducted exosomal proteomic and lipidomic analyses in OC and epithelial cells from the surface of the ovary and found that collagen type V alpha 2 chain (COL5A2) and lipoprotein lipase (LPL) were expressed at observably higher levels than those in epithelial cells on the surface of the ovary in the exosomes derived from OC cells. This indicated that proteins and lipids from exosomes have important significance in the inchoate diagnosis of OC.³⁷ Bhat et al discovered that Hh protein was preferentially exported in exosomes of CC cells, indicating that exosomal Hh protein may be a potential biomarker of CC.³⁸ These findings indicate the value of these proteins as potential biomarkers for prospective diagnosis and prognosis of female reproductive system cancers and BC.

Exosomal microRNAs

Exosomal miRNAs are critically involved in the initiation, progression, and metastasis of tumors by adjusting the stability of mRNAs or inhibiting their translation. Wang et al demonstrated that exosomal miR-1910-3p facilitated the propagation and transplantation of BC cells in vivo and vitro. MiR-1910-3p activates the wnt/β-catenin and NF-κB signaling pathways by downregulating muscle microtubulin-related protein 3 to promote BC development. Exosomal serum miR-1910-3p is a valid biomarker accompanied by the conventional biomarker CA153 and can improve the accuracy of BC diagnosis.³⁹ Wang et al found that cancer-associated fibroblast (CAF)-derived exosomes containing miR-181D-5p may play a crucial role in the CAF-adjusted BC tumor environment through CDX2 and HOXA5.⁴⁰ Lim et al found that the loss of miR-4516 in CAF-derived exosomes was related to the progression of FOSL1-dependent TNBC, and suggested the potential of miR-4516 as an anticancer drug for TNBC.⁴¹ Liu et al found that miR-3613-3p was upregulated in CAF exosomes, and the downregulation of exosomal miR-3613-3p inhibited the propagation and transplantation of BC cells by targeting SOCS2 expression, thus implicating miR-3613-3p as a therapeutic target in BC.⁴² Moloney et al showed a significant increase in exosomal miRNA-451a in the serum of BC patients, suggesting its importance as a potential new biomarker for BC.⁴³ Using RNA sequencing, Wu et al found higher exosomal levels of miR‑150‑5p, miR‑4665‑5p, and miR‑576‑3p in the miRNA profile of BC and proposed that these exosomal miRNAs can be used as novel biomarkers with predictive value for BC recurrence.⁴⁴ Li et al found that miR-148a in serum exosomes was markedly reduced in BC patients, and downregulation of exosomal miR-148a was closely related to the poor clinical prognosis of BC. These findings suggested that miR-148a in serum exosomes may be a promising diagnostic and prognostic biomarker of BC.⁴⁵ Maeda et al discovered that serum levels of exosomal miR-34a were dramatically increased in patients with early OC compared with those with advanced stage patients. The number of patients with lymph node metastasis was markedly lower and the number of patients in the recurrent disease group was also markedly lower. This demonstrated that serum exosomal miR-34a might be a biomarker that can be used to improve the diagnostic efficiency of OC.⁴⁶ Patients with epithelial ovarian cancer (EOC) are prone to peritoneal metastasis. The main immune cells in the peritoneum are M2 macrophages, especially tumor-associated macrophages (TAMs).⁴⁷ Li et al analyzed exosome microarrays in EOC and found that exosomal miR-221-3p and miR-221-3p accumulated in M2 macrophages directly inhibited cyclin-dependent kinase inhibitor 1B (CDKN1B). Low CDKN1B levels were connected with EOC advancement and unfavorable prognosis. This suggested that exosomal miR-221-3p may represent a neoteric biomarker in EOC.⁴⁸ Through studies of exosomes by the EOC cell derived in endothelial cells trigger angiogenesis-related signal events, Masoumi–Dehghi et al observed that exosomes containing miR-141-3p upregulated VEGFR-2 expression in endothelial cells, suggesting that EOC cell secretion of exosomal miR-141-3p is an important form of communication between cells and promotes endothelial cell migration and angiogenesis.⁴⁹ In a study of the regulatory effects of exosomal miR-205 on the pTEN-Akt pathway, He et al discovered that exosomal miR-205 was upregulated in OC tissues, and high miR-205 expression was related to the progression of metastasis in OC patients. This suggested that exosomal miR-205 might be a biomarker of OC.⁵⁰ Yeung et al reported that exosomal miR21 extracted from OC-related adipocytes (CAA) and fibroblasts (CAFs) was higher than that in OC cells. It was also shown that miR21 was transferred from CAA or CAF to cancer cells, where it combined with APAF1, a new target, to inhibit OC cell apoptosis and confer chemical resistance. These data suggested that exosomal miR21 from adjacent stromal cells alters the malignant phenotype of metastatic OC cells.⁵¹ Wu et al isolated exosomes from cervical vaginal fluid (CVF) during HPV16 infection, and discovered that hsa-miR-5590-3p was significantly downregulated in exosomes from HPV16-infected CVF-derived samples. Studies have shown that hsa-miR-5590-3p serves as a passive adjuster of the TGF/SMAD signaling pathway by downregulating TGF-R1 and SMAD4 transcripts, while the interaction of the TNF and TGF signaling pathways is closely associated with the occurrence of CC. These consequences suggested that exosomal hsa-miR-5590-3p plays a momentous role in the carcinogenesis related to HPV16 infection and may be a useful biomarker for the diagnosis of CC.⁵² Zhang et al found that the exosomal miR-221-3p promoted the proliferation, aggression, transference and angiogenesis of microvascular endothelial cells (MVECs) in CC by accommodating MAPK10, thus implicating miR-221-3p as a diagnostic biomarker of CC.⁵³ Wu et al also detected that exosomal miR-221-3p was transported from tumor cells to vascular endothelial cells in cervical squamous cell carcinoma (CSCC), although their role in promoting angiogenesis was mediated by downregulating THBS2.⁵⁴ These studies demonstrated that exosomal miR-221-3p is a novel biological marker in CC. Li et al discovered that exosomal miR-155-5p secreted by HIV-infected T cells were immediately targeted in ARID2 deterioration, and miR-155-5p facilitated the advance of CC by secreting proinflammatory cytokines. This suggested that exosomal miR-155-5p contributes to the malignant advancement of CC, offering underlying biomarkers for prophylaxis and treatment.⁵⁵ Compared with adjacent normal tissues, Zheng et al detected significant differences in the levels of exosomal let-7d-3P and miR-30d-5p in CC tissues, suggesting that they are valuable biological markers for the diagnosis and prediction of CC.⁵⁶ Shi et al found that EC cells secrete exosomes enriched in miR-133a, which downregulates FOXL2 in EC tissues. Further studies proved that EC cell-derived exosomes may be absorbed by stromal cells, suggesting that exosomal miRNAs contribute to the development of EC. These results highlighted new areas for the detection and treatment of EC.⁵⁷ Srivastava et al identified hsa-miR-200C-3p the most enriched miRNA in urine-derived exosomes of patients with EC. This suggested that differentially expressed miRNAs in exosomes can be used for the discovery of biomarkers and EC diagnosis, and that exosomal hsa-miR-200c-3p represents a non-invasive biological marker for the diagnosis of EC.⁵⁸ Li et al found that in EC, miR-148b is transferred from CAF to EC cells through exosomes, and that miR-148b inhibits EC metastasis by directly binding to its downstream target gene DNMT1 to mediate its anticancer effects.⁵⁹ In summary, these consequences indicate that exosomal miRNAs not only provide new non-invasive diagnostic methods, but also represent prospective prognostic biomarkers of female reproductive system cancers and BC.

Exosomal lncRNAs and circRNAs

In addition to miRNAs, exosomes are known to contain several other non-coding RNAs, including lncRNAs and circRNAs, which also play significant regulatory roles in female reproductive system cancers and BC. Exosomes communicate with cells through transporters including lncRNAs, which are considered to represent promising non-invasive biomarkers. Zhong et al found that exosomal lncRNA H19 expression was upregulated in BC patients, and receiver operating characteristic (ROC) analysis revealed the high diagnostic accuracy of exosomal lncRNA H19.⁶⁰ Expression of the 2.2-Kb lncRNA HOTAIR^61,62 is associated with malignant tumors, including BC⁶³ and OC.⁶⁴ Tang et al demonstrated that HOTAIR in serum exosomes of BC patients was present at higher level than that in normal individuals. Moreover, this high expression was associated with poor responses to neoadjuvant chemotherapy and tamoxifen, suggesting that serum exosomal HOTAIR may be a biological marker of BC.⁶⁵ Zhang et al found that exosomes secreted by OC cells inhibited the PTEN/AKT signaling pathway through the transfer of lncRNA FAL1, thus inhibiting the metastasis of OC cells both in vitro and in vivo. This may provide a new perspective for an in-depth understanding of the mechanism of OC and the search for novel targets for targeted molecular therapy.⁶⁶ Tang et al evaluated the expression profile and clinical value of serum exosomal lncRNA antisense hypoxia induction factor (aHIF) in EOC. It was found that EOC patients with high serum exosomal aHIF expression had a poor overall survival, suggesting that exosomal aHIF may be a promising biomarker of poor prognosis.⁶⁷ Metastatic lung adenocarcinoma 1 (MALAT1) is a renowned lncRNA related to tumor angiogenesis and transfer.⁶⁸ Qiu et al demonstrated that MALAT1 was diverted to recipient human umbilical vein endothelial cells (HUVECs) through exosomes, and influenced HUVECs by stimulating the expression of angiogenesis-related genes that ultimately promoted angiogenesis. In addition, circulating exosomal MALAT1 is a prospective serum-based non-invasive biological marker in EOC.⁶⁹ Guo et al found that LncRNA-EXOC7 expression in serum and exosomes was related to the FIGO stage of CC. Treatment and recurrence were correlated by detecting lncRNA-EXOC7 in the serum of patients with CC and exosomes derived from serum. This suggested that serum and exosomal lncRNA-EXOC7 are important biomarkers for diagnosis, evaluation of treatment efficacy and detection of CC recurrence.⁷⁰ Zhang et al demonstrated differential levels of exosomal HOTAIR, MALAT1 and MEG3 isolated from cervical vaginal lavage of patients with CC compared with cancer-free volunteers. This suggested that exosomal lncRNAs have potential value for inchoate monitoring of CC, and can be used as expedient and noninvasive biological markers.⁷¹ TUG1 is an lncRNA that promotes the development of CC by promoting cell proliferation and inhibiting apoptosis.⁷² Lei et al found that exosomal TUG1 in CC promoted HUVEC proliferation by inhibiting caspase-3 activity and regulating the expression of apoptosis-related proteins, indicating that this is the mechanism by which CC cells promote angiogenesis and offering a prospective target for early diagnosis.⁷³

The application of circRNAs in exosomes is also of great significance for tumor development. Yang et al detected significant differences in the expression of hsa-circRNA-0005795 and hsa-circRNA-0088088 in CC serum exosomes and tissues.⁷⁴ Wang et al also identified other differentially expressed circRNAs from exosomes in BC cells and BC patients, including hsa-circ-0009634, hsa-circ-0020707, hsa-circ-0087213, hsa-circ 0064923, hsa-circ-0104852, hsa-circ-0087064 and hsa-circ-0126527.⁷⁵ Detection of these circRNAs has been used to improve the diagnosis and treatment of BC. Guan et al investigated the function and potential mechanisms of circPUM1 in OC, found that circPUM1 increased the expression of nuclear factor B (NF-κB) and MMP2 by sponging miR-615-5p and miR-6753-5p. In-depth studies demonstrated that exosomal circPUM1 acted on peritoneal mesothelial cells and promoted cancer metastasis. These findings suggested that exosomal circPUM1 not only facilitates the propagation, transference and aggression of OC, but also acts on the peritoneum and promotes tumor metastasis.⁷⁶ Mao et al analyzed the circEIF4G2 expression levels and the clinicopathological data of CC patients, and found that circEIF4G2 expression in HeLa cells was dramatically higher than that in primary cervical epithelial cells. This suggested that the increased expression of circEIF4G2 in CC tissues and serum may be caused by circEIF4G2 secreted by CC cell exosomes, and that circEIF4G2 represents a marker for the diagnosis of cervical lesions.⁷⁷

These results indicate that exosomal lncRNAs and circRNAs are also potential biomarkers of female reproductive system cancers and BC.

Exosomal DNAs

Tumor-derived exosomes frequently carry particular genes that can be tested to monitor tumor progression.⁷⁸ Shi et al discovered that activation transcription factor 1 (ATF1) and RAS genes were markedly upregulated in mouse models of primary and recurrent CC, and were also found in blood exosomes in mouse models. This suggested that exosomal RAS and ATF1 may be latent biological markers for initial diagnosis of CC.⁷⁹ Exosomes may function as a vector for viral DNA. Mata–Rocha et al detected HPV DNA, including the viral oncogene E6/E7, in the exosomes of HeLa cells and cervical samples, suggesting that viral DNA-modified exosomes may be involved in intercellular communication by transmitting oncomolecules to adjacent cells.⁸⁰ Acellular cyclic DNA molecules can be delivered by almost all types of cells, combine with macromolecular compounds or cytomembranes or be internalized by vesicles.⁸¹ Measurements of the number of mitochondrial DNA copies in whole blood (wb-mtDNA) and adtevak (between cells and exosomal containing mtDNA) in patients with serous epithelial OC showed that the mtDNA copy number was the highest in exosomes, and there were significant differences in wb-mtDNA copy numbers between normal controls and patients with early and advanced tumors. This suggested that changes in mtDNA copy number in OC may signal cancer progression, and that wb-mtDNA may even provide information about the emergence of early serous OC.⁸² These studies suggest that exosomal DNA may also be involved in the communication process between tumor cells and could be an underlying biological marker for early diagnosis of female reproductive system cancers and BC.

The Function of Exosomes in the Immune Response of Female Reproductive System Cancers and Breast Cancer

Tumor cells secrete immunoactive exosomes that inhibit tumor growth via anti-tumor immune responses,⁸³ and facilitate the progression of cancer by inhibiting anti-tumor immunity⁸⁴ or enhancing metastasis.⁸⁵

The Function of Exosomes in the Immune Response of Breast Cancer

The immune escape of tumor cells is conducive to the etiopathogenesis of BC. Yao et al found that endoplasmic reticulum stress facilitated exosomal excretion and increased exosomal miR-27a-3p expression in BC cells, and miR-27a-3p upregulated PD-L1 via the MAGI2/PTEN/PI3K axis to promote the immune escape of BC.⁸⁶ Macrophages play a dual role in the emergence and progression of tumors, and can promote and inhibit tumors.⁸⁷ Sen et al showed that macrophage migration increases following exposure to exosomes produced by BC cells under conditions of high temperature, and the liberation of key chemokines, such as TNF-α or RANTES, in turn, may transform the accommodative immune response. This research suggested that exosomes liberated by tumor cells exposed to mild hyperthermia have a potential immunogenic effect.⁸⁸ γδT cells are the main element of tumor-infiltrating lymphocytes (TILs) in BC and are related to poor pathologic features and unfavorable prognostic.⁸⁹ Ni et al demonstrated that BC-derived exosomes (TDEs) transferred the upregulated CD73 expression of the lncRNA SNHG16 to γδ1 cells. This was mediated by the enhanced activation of the TGF-β1/SMAD5 signaling pathway by the BC-derived exosomal SNHG16/miR-16-5p/SMAD5 regulatory axis, thus producing CD73 expression in Vδ1 T cells. These consequences confirmed the importance of CD73 +Vδ1Treg cells in BC and the potential for future BC therapy targeting this subgroup or blocking TDE.⁹⁰ By studying the tissue-specific effects of exosomes from highly metastatic BC cells on immune components, Wen et al determined that BC exosomes directly inhibited T cell proliferation and NK cell cytotoxicity, which may inhibit anti-cancer immune responses in pre-metastatic organs. This finding provides novel insights into the tissue-specific outcomes of BC-derived exosomal accumulation and its contribution to immunosuppression and the promotion of metastasis.⁹¹ Ham et al found that BC-derived exosomes partially induced IL-6 secretion and a pre-survival phenotype in macrophages through glycoprotein 130 (GP130)/STAT3 signaling. These results provide evidence of the role of exosomes in facilitating cargo exchange between BC and immune cell subsets (Figure 3A).⁹²

Figure 3.

(A). Tumor cells secrete immunologically active exosomes that act on immune cells (macrophages, γδT cells and T cells) to change tumor immune response and affect tumor growth. (B). Dendritic cells from tumors secrete immunologically active exosomes to change the tumor immune response and affect tumor growth.

The Function of Exosomes in the Immune Response of Female Reproductive System Cancers

The immune microenvironment is also critical for the development of EOC and consists of TAMs and T lymphocytes, such as regulatory T cells (Treg) and T helper 17 (Th17) cells.⁹³ Zhou et al demonstrated that the Treg/Th17 ratio in both in situ EOC and metastatic peritoneal tissue was markedly higher than that in benign ovarian and peritoneal tumors. Enrichment of miR-29a-3p and miR-21-5 can be found in exosomes derived from TAMs. They regulate the reciprocity between TAMs and T cells, eliciting the immunosuppressive microenvironment that promotes EOC progression and metastasis.⁹⁴ TAMs are the most common immune-relevant stromal cell in the tumor microenvironment (TME), and the communication between tumor cells and TAMs is involved in the development of EOC.⁹⁵ Chen et al found that exosomes derived from EOC cells promoted remodeling of macrophages into tumor-promoting TAM phenotype. The study revealed that exosomal delivery of miRNAs derived from EOC cells induced M2 macrophage polarization under hypoxic conditions, thereby promoting EOC cell propagation and transplantation. This research suggested that these exosomes and relevant miRNAs may act as potential targets for novel biological markers for EOC.⁹⁶ Li et al demonstrated that OC cells secrete exosomes to recruit lymphocytes into the tumor microenvironment to inhibit anti-tumor immunity (for example IL10) and strengthen cancer aggression, vasculogenesis, and the transmission of proinflammatory cell factors. This suggested that lymphocyte-cancer cell crosstalk through exosomes could contribute to the advancement of valid immunotherapy strategies for OC.⁹⁷ Shenoy et al identified ganglioside GD3 as an inhibitory lipid in exosomes that exist in the ovarian tumor microenvironment, and demonstrated that these exosomes have a causal relationship with the T cell immunosuppression. Further studies revealed that the inhibitory ability of GD3 was directly associated with sialic acid residues, and targeting GD3 or sialic acid residues is a feasible approach to combating GD3-regulated immunological suppression.⁹⁸ Small heat shock proteins (sHsps) are a group of chaperones that are involved in the pathogenic mechanism of various autoimmune-mediated diseases and cancers.⁹⁹ Wyciszkiewicz et al found that the exosomes from OC patients and EC or endometriosis patients had higher levels of sHsp compared with the levels detected on serum and peritoneal fluid. Furthermore, it was shown that sHsp expression levels were positively correlated with the expression of perforin and granzyme B, which are markers of cytotoxic immune responses. This approach may have broad prospects for the early diagnosis of OC and exploration of the pathogenesis of autoimmune-mediated diseases and cancers.¹⁰⁰ Dendritic cell (DC)-derived exosomes (Dexs) have been revealed to produce specific anti-tumor immune responses both in vitro and vivo.¹⁰¹ Chen et al found that poly (I: C) greatly enhanced the effective antineoplastic immunity induced by antigen pulsed Dexs and improved the efficacy of CC.¹⁰² Ren et al investigated the effect of DCs loaded with HeLa cell-derived exosomes (HeLa-exo) on CC on cytotoxic T lymphocyte (CTL) responses and the cytotoxic effect of CTLs on HeLa cell lines. It was found that DCs loaded with HeLa-exo promoted T cell proliferation and induced CTL responses, thereby inhibiting the growth of CC cells in vitro (Figure 3B).¹⁰³ Epstein–Barr virus (EBV) is a carcinogenic herpes virus associated with a variety of human epithelial and lymphatic malignancies. EBV-encoded small RNAs (EBERs) are expressed in large quantities and secreted by exosomes in EBV-infected cells.¹⁰⁴ These transcripts promote innate immune regulation and cell growth. Aromseree et al found that high levels of EBER1 in cervical cells or invasive DC exosomes may play a role in the inflammatory transformation of HPV-related CC by modulating innate immune signals.¹⁰⁵

These studies indicate that exosomes participate in the pathogenesis of tumors by affecting the immune response to tumors, indicating that these exosomes have broad prospects for the diagnosis and immunotherapy of female reproductive system cancers and BC.

Exosomes Induce Drug Resistance in Female Reproductive System Cancers and Breast Cancer

Exosomes Induce Drug Resistance in Breast Cancer

Exosome-mediated drug resistance is a crucial challenge in cancer therapy. Mounting evidence suggests that tumor-derived exosomes may transform the extracellular substrate by secreting or activating matrix metalloproteinases (MMPs).¹⁰⁶ Sadegh–Nejadi et al found that circulating exosomes in the plasma of obese women promoted the propagation, migration and aggression of BC cells as well as the activation of MMP2 and MMP9. Circulating plasma exosomes in obese women may also lead to tamoxifen resistance of BC cells.¹⁰⁷ Han et al found that the lncRNA actin filament-associated protein 1 antisense RNA 1 (AFAP1-AS1) is related to trastuzumab resistance. Receptor tyrosine-protein kinase erbB-2 (ERBB2) is one of the most studied oncogenes and is considered a biomarker of BC. It was found that exosomal AFAP1-AS1 induced trastuzumab resistance by binding to AU binding factor 1 (AUF1) and facilitating ERBB2 translation. Consequently, exosomal AFAP1-AS1 levels can be used to predict trastuzumab resistance and treatment efficacy in BC.¹⁰⁸ Pan et al suggested that miR-221-3p in drug-resistant BC cell-derived exosomes targets PIK3R1 via the PI3K/AKT both in vivo and vitro, thereby enhancing BC cells resistance to adriamycin (ADR).¹⁰⁹ Santos et al demonstrated miR-155 induction in exosomes isolated from cancer stem cells (CSCs) and drug-resistant cells, and also showed that exosomes in BC cells may mediate resistance and migration to sensitive cells in part through the migration of exosomes containing miR-155. This finding confirmed the importance of exosome-mediated miR-155 resistance in BC cells.¹¹⁰ Dong et al demonstrated that exosomal regulated diversion of lncRNA-SNHG14 induced trastuzumab resistance in BC cells, and that exosome lncRNA-SNHG14in human serum could be considered as an underlying diagnostic biological marker for BC to improve trastuzumab treatment efficacy.¹¹¹

Exosomes Induce Drug Resistance in Female Reproductive System Cancers

Alharbi et al studied the role of platinum in heterogeneous populations of OC cells and their derived exosomes, and found that miR-21-3p, miR-21-5p and miR-891-5p were enriched in exosomes. These exosomal miRNAs could play a role of chemotherapy resistance in OC by upregulating detoxification metabolic pathways and DNA repair mechanisms.¹¹² Asare–Werehene et al demonstrated increased expression and secretion of plasma gelsolin (pGSN) in chemotherapy-resistant OC cells compared with the chemically sensitive counterparts. pGSN is secreted and carried by exosomes (ex-pGSN) to upregulate HIF1α-induced pGSN expression via an autocrine pathway in chemotherapy-resistant OC cells and induces cisplatin resistance in other chemosensitive OC cells.¹¹³ Zhu et al found that exosomes derived from anoxic macrophagocytes strengthened the tumorigenic phenotype of EOC cells. Furthermore, under hypoxic conditions, macrophage-derived exosomes rich in miR-223 promoted chemoresistance of EOC cells via PTEN-PI3K/AKT.¹¹⁴ Li et al observed that urothelial carcinoma-associated 1 (UCA1) was upregulated in tissues and cell lines of cisplatin-resistant patients, and inhibition of UCA1 promoted miR-143 expression and regulated the expression of FOSL2 in OC to promote cisplatin resistance.¹¹⁵ Cao et al demonstrated that DNMT1 counterparts were highly concentrated in exosomes of OC cells, and co-incubation with exosomes promoted endogenetic expression and made host cells resistant to cisplatin cytotoxicity. These results elucidated new mechanisms of cisplatin resistance in OC foreign secrete DNMT1 and indicated the potential of exosome inhibitors combined with cisplatin in drug-resistant patients.¹¹⁶ Kanlikilicer et al found that miR-1246 expression in paclitaxel-tolerant OC exosomes was significantly higher than in the sensitive counterparts, while Cav1 gene was the specific target of miR-1246 and participated in the process of exosome transfer. Cav1 overexpression and anti-miR-1246 therapy markedly sensitized OC cells to paclitaxel. This research provided a novel therapy to overcome chemical resistance in OC patients with exosomal miR-1246.¹¹⁷ Guo et al showed that CDKN1A was highly expressed in cisplatin sensitive OC cells, and exosomal miR-98-5p targeted CDKN1A to restrain CDKN1A expression. These results suggested that CAF-derived exosomes transferred the overexpressed miR-98-5p to facilitate cisplatin resistance in OC by downregulating CDKN1A.¹¹⁸ Luo et al found that exosomal lncRNA HNF1A-AS1 was upregulated in DDP-resistant (HeLa/DDP) cells, and HNF1A-AS1 acted as a competitive endogenous RNA (ceRNA) of miR-34b, promoting the expression of TUFT1 and consequently promoting DDP resistance in CC cells.¹¹⁹

These studies revealed a new mechanism underlying exosome-mediated tumor chemoresistance, and also demonstrated the potential of exosome inhibitors for the treatment of drug-resistant female reproductive system cancers and BC (Figure 4).

Figure 4.

The proposed function of exosomes in the regulation of tumor chemotherapy resistance.

The Role of Exosomes for Drug Delivery in Female Reproductive System Cancers and Breast Cancer

The Role of Exosomes in Breast Cancer Drug Delivery

Exosomes have been used to deliver biomolecules and chemotherapeutic drugs for tumor treatment. Han et al successfully isolated exogenous hormones derived from natural killer cells (NK-Exos) by ultra-high speed centrifugation, and prepared a PTX-NK-Exos drug delivery system using NK-Exos as castor oil-based PTX carrier by electroporation. It was found that PTX-NK-Exos played an anti-tumor role in BC cells by inducing the upregulation of Bax and Caspase-3 in the apoptosis signaling pathway of tumor cells. This finding indicated that exosomes loaded with drugs could effectively inhibit the proliferation and induce tumor cell apoptosis, thus playing an anti-tumor role in BC cells.¹²⁰ Exosomes are the perfect choice for gene targeting on account of their innate non-toxic, non-immunogenic,¹²¹ biodegradable and targetable characteristics. Limoni et al adopted the Her2-specific anchor protein repeat protein (DARPins)¹²² developed by Plueckthun to produce Her2-targeted exosomes, which were used to deliver siRNA to Her2-overexpressing BC cells. Studies have shown that targeted exosomes can be successfully loaded with high levels of siRNA and used in Her2-positive BC gene therapy. This approach offers a variety of options for gene therapy and drug delivery.¹²³ Exosomes derived from human mesenchymal stroma/stem-like cells (MSCs) have shown significant biocompatibility and reduced innate immunogenicity, thus representing valuable vectors for drug delivery in oncology therapies. Catharina et al found that drug-loaded MSC-derived exosomes showed excellent in vitro cytotoxicity by effectively targeting primary and metastatic tumors and reducing side-effects in BC cell populations and in vivo, offering promising treatment prospects for BC.¹²⁴

The Role of Exosomes in the Female Reproductive System Cancer Drug Delivery

Kobayashi et al demonstrated that therapy with miR199a-3p-loaded-exosomes (miR-199a-3p-Exo) greatly enhanced miR199a-3p expression in OC cells, and that miR-199a-3p-Exo suppressed the expression of C-Met, the specific target of miR199a-3p, hence inhibiting cell propagation and aggression. These results suggested that exosomes derived from OC patients could be used as a novel drug delivery system (DDS) for prospective targeted molecular therapies.¹²⁵ Liu et al constructed a triptolide-loaded exosome delivery system (TP-Exos) and observed its effect on the propagation and apoptosis of OC cells in vitro and vivo. The results showed that TP-Exos have the normal features of exosomes, as well as exhibiting advanced drug encapsulation efficiency, suggesting that TP-Exos may be a promising treatment strategy for OC.¹²⁶ Kim et al discovered that tumor cell-derived exosomes act as natural vectors for effective delivery of the CRISPR/Cas9 plasmid to cancer cells. Exosomes loaded with CRISPR/Cas9 inhibited the expression of poly (ADP-ribose) polymerase-1 (PARP-1), leading to the induction of OC cell apoptosis. These results suggested the promise of tumor-derived exosomes for drug delivery in tumor therapy.¹²⁷ Zhang et al studied the clinical significance and biological function of miR-320a encapsulated in EVs released by CAFs in EC. The results showed that the miR-320a encapsulated in exosomes secreted by CAF was directly transferred to EC cells, thereby inhibiting their proliferation. This effect which was achieved by miR-320a-induced downregulation of HIF1α, leading to decreased expression of VEGFA in vitro. These results suggested that CAF-derived EVs overexpressing miR-320a offer a new direction for EC treatment strategies.¹²⁸ These studies suggest that tumor-derived exosomes can facilitate drug delivery, which could have broad prospects for the therapy of the female reproductive system cancers and BC.

Application of Exosomes in the Nanotherapy of Female Reproductive System Cancers and Breast Cancer

Roles of Exosomes as Nanocarriers in Nanotherapy

In recent years, the application of exosomes in tumor treatment has been extensively studied, and the nanotherapy of exosomes has better research value. Exosomes are endogenous nanoparticles secreted by a variety of cells and have been explored as drug delivery nanocarriers.^129,130 Zhao et al developed exosome membrane-coated nanoparticles that can protect siRNA from degradation and have excellent biocompatibility. Further studies in vivo showed that exosomal membrane-coated nanoparticles had higher affinity, which significantly inhibited the growth of malignant BC cells.¹³¹ Tran et al loaded aspirin into exosomes as an anticancer agent, and converted crystalline aspirin into the nano-amorphous form in exosomes with a nano-matrix structure, thereby improving the efficiency of drug encapsulation of exosomes and the dissolution and cytotoxicity of aspirin in BC. Thus, in this study, a novel nano-amorphous exosome delivery system consisting of nanorods was created that can transform anti-inflammatory drugs into effective cancer drugs.¹³² By in vivo adoptive transfer of bone marrow MSCs in CC mice, Naseri et al demonstrated that MSCs-Exo permeate tumor sites and act as an appropriate nanocarriers for the delivery of inhibitory oligonucleotides into neoplastic tissues to downregulate the expression levels of miR-142-3p and miR-150.¹³³ Aqil et al found that exosomes containing Anthos exhibited marked anti-proliferative activity against OC cell development and restrained tumor development more effectively compared with the effects of Anthos from berries and carrier controls alone. Anthos has been shown to be effective against OC, and milk exosomes are excellent nanocortors that enhance oral bioavailability of drugs for the treatment of OC.¹³⁴ Aqil et al further demonstrated that exosomal curcumin (ExoCUR) showed stronger anti-proliferative and anti-inflammatory activity in BC and CC cell lines (as measured by NF-κB activation) compared with free curcumin, suggesting that exosomes are suitable for development as potential nanocarriers to deliver curcumin to improve tissue bioavailability.¹³⁵

Other Roles of Exosomes in Nanotherapy

Reprogrammed exosomes can be used as nanocontrollers of cellular immunity. Cheng et al found that endogenous exosomes can be used as artificial cellular immune controllers to redirect immune effector cells and regulate their immune reactivity in BC cells. This exosome-based nano-agent provides unique and enhanced pharmacological properties that can be used to develop new therapies for BC.¹³⁶ Endogenous exosome levels may also affect the efficiency of nanoparticles for targeted drug delivery. Wang et al found that pre-treatment with peripheral blood-derived exosomes reduced the deposition grapefruit-derived nanovector (GNV) in the liver and improved the treatment efficiency of GNV-carrying drugs in BC mice.¹³⁷ These studies demonstrate the role of exosomes in nanotherapy and open a new chapter in the treatment of female reproductive system cancers and BC.

Clinical Trials of the Use of Exosomes to Treat Female Reproductive System and Breast Cancers

Several clinical trials have been reported in recent years that further clarify the role of exosomes in the treatment of female reproductive system and breast cancers. Human mesenchymal stem cells (MSCs) have a well-established tumor homing capability, highlighting their potential as a delivery vehicle for targeting tumors.¹³⁸ Makiko et al co-cultured BC cells with bone marrow mesenchymal stem cells (BM-MSCs) isolated from human donors. An increase in miR-23b was observed in BM-MSC-derived exosomes, and the miR-23b overexpression induced a dormant phenotype by inhibiting the target gene MARCKS. These findings indicated that the transfer of miRNAs from the bone marrow-derived exosomes of BC patients may promote the dormancy of breast cancer cells in the metastatic niche to achieve the effective treatment of BC.¹³⁹ Senthilkumar et al isolated exosome simulators (EM) from BM-MSCs in breast cancer patients, mixed the cells with paclitaxel (PTX), and isolated PTX-loaded EM (PTX-MSC-EM), which were found to significantly inhibit the growth of BC.¹⁴⁰ O’Brien et al found that miR-379 expression was significantly reduced in lymph node metastasis compared with BC tumor tissues from the same patients. MSC-379 secreted by MSC exosomes encapsulates COX-2 as an effective tumor suppressor in BC, showing exciting potential for innovative therapies for metastatic BC.¹³⁸ Musa et al found that conditioned medium (CM) derived from human fat MSC (hAMSC) inhibited OC cells by blocking the cell cycle and activating mitochondria-mediated apoptosis signal transduction. Exosomes derived from hAMSC-CM induced apoptotic signals by upregulating different pro-apoptotic signaling molecules (such as BAX, CASP9 and CASP3) and downregulating the anti-apoptotic protein BCL2. Moreover, exosomal miRNAs are important participants in the inhibitory effect of hAMSC-CM on OC cells. These results will provide new advances in the research and treatment of OC.¹⁴¹ Li et al found that the presence of tumor-specific antigens on exosomes isolated from malignant ascites of ovarian cancer patients could be presented by DC from unrelated cord blood sources, thus inducing tumor-specific cytotoxicity, which may represent a new immunotherapy for OC.¹⁴² Niko et al also isolated exosomes from the malignant ascites of patients with OC, and showed that the secretion of body in mononuclear precursor cells may also trigger in other immune cells dependence toll-like receptor (TLR) signaling pathway. This process reveals that ovarian cancer and inflammatory diseases are induced through an immunosuppressive mechanism, and that immune therapy of OC is crucial.¹⁴³ These studies suggest that exosomes isolated from MSCs and malignant ascites from cancer patients may have specific inhibitory effects on female reproductive system and breast cancers, and these results will provide new advances in the research and treatment of female reproductive system and breast cancers (Table 4).

Table 4.

Overview of Clinical Trials of Using Exosomes to Treat Female Reproductive System and Breast Cancers

Cancer	Exosome	Donor Cell	Recipient Cell	Pathway	Function	Reference
Breast CA	miR-23b	mesenchymal stem cells(MSC)	Breast CA cells	inhibiting the target gene MARCKS	therapy	[139]
Breast CA	Exosome mimetics (EMs)	MSC	Breast CA cells	As drug delivery vehicles	Therapy	[140]
Breast CA	miR-379	MSC	Breast CA cells	As drug delivery vehicles	Therapy	[138]
Ovarian CA	Exosome mimetics (EMs)	Human fat MSC (hAMSC)	Ovarian CA cells	blocking cell cycle and activating mitochondria-mediated apoptosis signal transduction.	Therapy	[141]
Ovarian CA	Exosomal proteins	Malignant ascites of ovarian cancer patients	Ovarian CA cells	Presenting tumor-specific antigens	Therapy	[142]
Ovarian CA	Exosomal proteins	Malignant ascites of ovarian cancer patients	Ovarian CA cells	The knockdown of Toll-like receptor 2 (TLR2) and TLR4 blocked NFκB and STAT3 activation	Therapy	[143]

Challenges and Future of Exosomes

Our knowledge of exosomes has grown dramatically in recent years. Exosomes have been shown to be important modulators in tumor biology, and tumor-derived exosomes containing tumor-specific antigens and nucleic acids can be used as potential diagnostic and predictive biomarkers for noninvasive assessment. Exosomes are also used to identify patients who may develop metastatic disease, and the production of exosomes may provide new targets for cancer treatment. The use of exosomes as a carrier of cellular information is a promising strategy in the field of targeted drug delivery in the treatment of cancer, and improved functional exosome mimics have greatly improved drug acceptability in this DDS. However, more efficient and widespread use of exosomes is still problematic. For example, drug delivery systems require nucleic acid drugs to be effectively transfected into exosomes, and host cells suitable for exosome injection pose a challenge for future clinical applications. Appropriate cell selection can also determine the natural population of exosome surface proteins, which ensures ideal ligand-receptor interactions with the proposed target cell. Optimization of the producer-target cell combination is critical to the production of exosomes for therapeutic use. Despite these potential drawbacks and reservations, this area of research is highly dynamic and promises to provide novel approaches to the diagnosis and treatment of cancer patients. In addition, the accurate isolation, identification and high-throughput clinical application of EVs face great challenges. The further development of cancer exosome proteomics and the improvement of microfluidics technology to detect exosomes will improve their application in cancer diagnosis.

Conclusion

The current research on exosomes has reshaped our understanding of exosomes and provided new targets for cancer diagnosis and treatment. In this review, we describe the biogenesis of exosomes and the main mechanisms of exosome-mediated immunity, chemoresistance, and drug delivery. Regarding clinical applications, our review helps to understand the role of exosomes as biomarkers, nanotherapy in female reproductive system cancer and breast cancers, and clinical trials of the use of exosomes. However, it must be pointed out that the key components of exosomes have not been fully clarified, and there is still a long way to go to fully understand the role of exosomes in female reproductive system cancer and breast cancers. More extensive and in-depth research is still needed to fully understand the role of exosomes and to develop exosome-based clinical programs for the diagnosis, prognosis and treatment of female reproductive system cancer and breast cancers in the future.

Funding Statement

This study was funded by Jilin Province Financial and Health Project(Research on the Differential Expression of Cyclic RNA in Cervical Cancer HeLa Cells and the Mechanism of Radiation Resistance under Radiation Induction); Jilin Provincial Department of Finance (Consortium of Medical Consortium for Diagnosis and Treatment of Difficult Women’s Tumors and Precision Radiotherapy Training Base Construction project); Jilin Province Medical and Health Talent Special Project (2019SCZT010).The funders had no role in study design, decision to publish, or preparation of the manuscript.

Disclosure

The authors report no conflicts of interest in this work.